Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy

To the Editor I read with great interest the recent study published in JAMA Ophthalmology by Hathaway et al warning of an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) among patients starting treatment with semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), either for type 2 diabetes or for overweight or obesity. Their findings from a retrospective matched cohort study showed a 4 times higher risk of being diagnosed with NAION among patients with diabetes, while this risk was 7 times higher in people who were overweight or obese.

This post was originally published on this site